August 18, 2019

Statement from Sundial

Sundial is aware of an online article involving a commercial relationship with another Licensed Producer. There were factual inaccuracies in the article. While Sundial cannot comment on specific customer agreements due to contractual confidentiality, we can confirm that this isolated immaterial matter is being resolved between Sundial and the Licensed Producer. There is no impact on Q2 financial reporting and we anticipate that the impact on Q3 earnings will be negligible. Sundial follows strict Good Production Practices (GPP) in accordance with all Health Canada standards. Our company also uses standard provisions for potential returns which is consistent with industry practice.

Sundial is committed to producing safe, innovative and high-quality products.

Latest News

View All

Thursday, Jan 09, 2020

Sundial and Vir Pharmaceuticals Sign Medical Cannabis Supply Agreement for Australian Chronic Pain Clinical Studies

Sundial and Vir Pharma announced a three-year agreement where Sundial will supply medical cannabis oil for Vir Pharma's unique oral formulation for chronic pain that will be used for clinical studies in Australia.

Read More

Thursday, Dec 19, 2019

Sundial Announces 2020 Launch of Medical Cannabis Marketplace

Sundial is pleased to announce an initiative to enter the Canadian medical cannabis business with plans for an innovative e-commerce marketplace.

Read More

Wednesday, Dec 18, 2019

Sundial Announces New Board Member Bryan Pinney

Sundial and Greg Mills, Chair of the Board, are pleased to announce that Bryan Pinney has been appointed to the Board of Directors, effective December 18, 2019.

Read More
image/svg+xml logo logo Created with Sketch.


Thanks, but unfortunately you need to be legal age to view our website.


You need to be of legal age to view our website.

Please choose a province and enter your date of birth to continue.


Date of Birth

By entering this site you agree to our